Viral Vector Manufacture

30 March -1 April 2020 | Business Design Centre London

 

 

2000+
Attendees
700+
1-2-1 Meetings
300+
Speakers
100+
Exhibitors
12
Streams

 

 

Viral Vector Manufacture

VIRAL VECTOR MANUFACTURE, Tuesday 31 March 2020

CONFERENCE DAY 1 - TUESDAY 31st March 2020

Opening Keynotes Day 1 – CAR-T & Immunotherapy focus

Prasad Adusumilli
09:00

Keynote presentaton: Autologous Mesothelin-targeting CAR-T to tackle solid tumours in the clinic

  • The presentation will highlight results to date of mesothelin-targeted CAR T-cell clinical trial results
  • Advances in preclinical research of CAR T-cell therapy for solid tumors will be presented
  • Novel strategies for overcoming hurdles to solid tumor CAR T-cell therapy will be discussed
Panel discussion
09:20

Realizing the promise of ATMPs for patients around the world

  • Working with regulators to navigate scale up challenges in manufacturing
  • Strategies in supply chain and patient delivery
  • Tackling post manufacturing commercialization challenges such as pricing and finding highly skilled experts
  • Durability
10:20

Morning Coffee Break

Mark Sawicki
11:40

Effective Integration Strategies Through a Compliance Unified Ecosystem (CUE)

  • Systems Integration continues to be a major issue in the production and distribution of Advanced Therapies
  • Well-defined strategies for the integration of independent informatics platforms will be critical for future standardization and workflow optimization
  • Cryoport’s Compliance Unified Ecosystem (CUE) is driving standard practices for systems integration in the industry
round tables
12:00

Technology and Strategy Roundtables will run from 12:00-12:45 with 15 minutes for a quick summary from each table at the front of the room. These will take place in the conference rooms: look for you

Technology and Strategy Roundtables will run from 12:00-12:45 with 15 minutes for a quick summary from each table at the front of the room. These will take place in the conference rooms: look for your table number to participate.
1. Raw material supply for the commercial manufacturing of cell and gene therapies
Frank Hecht

Frank Hecht, Vice President Marketing And Sales, CellGenix GmbH

11. Cord blood as a source of new cells
12. Tissue engineering for organ regeneration
Vaidehi Joshi

Vaidehi Joshi, Scientist II, Therapeutics,, Organovo

13. TBC
14. Making allogeneic cell therapy a reality
Devyn Smith

Devyn Smith, Chief Operating Officer and Head Of Strategy, Sigilon

15. Industry-no profit alliances: how to optimize synergies
Elena Beltrami

Elena Beltrami, Business Development Manager, Fondazione Telethon

17. How companies can interact with the regulator and various pitfalls to be aware of
John Johnston

John Johnston, Clinical Assessor, Medicines & Healthcare Products Regulatory Agency

19. Roundtable available
2. Physiological conditions and analytical and monitoring tools for 3D cell cultivations
Cornelia Kasper

Cornelia Kasper, Professor, Biopharmaceutical Production And Technology, B.O.K.U.

21. Neurological applications for ATMPs
22. Development of regenerative medicines for cardiovascular indications
David Mazzo

David Mazzo, Chief Executive Officer, Caladrius Biosciences

23. Renal applications for ATMPs
24. Tackling diabetes with ATMPs
3. TBC (Reserved for Schott)
Sebastian Kress

Sebastian Kress, Post Doc, BOKU

5. Considerations for manufacture scale-up from academia to commercial manufacturing
Johannes Van Der Loo

Johannes Van Der Loo, Clinical Vector Core Director, The Children's Hospital of Philadelphia

9. Exploring the crossover between human and veterinary applications for stem cells
Joanna Miller

Joanna Miller, Chief Scientific Officer, Cell Therapy Sciences

13:00

Lunch

Palani Palaniappan
VIRAL VECTOR MANUFACTURE
14:20

Developing robust manufacturing processes for novel gene therapies

Francesca Bellintani
VIRAL VECTOR MANUFACTURE
14:40

Large Scale Production of LV and RV Vectors for T- and CD34+ Cells Transduction

Manuel Carrondo
VIRAL VECTOR MANUFACTURE
15:00

Continuous downstream processing, from gene therapy viruses to exosomes

Jean-Philippe Combal
VIRAL VECTOR MANUFACTURE
15:40

Collaborative strategy for AAV Manufacturing for Biotech: is In or Out the only model?

Devyn Smith
VIRAL VECTOR MANUFACTURE
16:00

Case study: In-house manufacture vs. outsourcing – why and when?

16:20

Afternoon Break

Leonard Pattenden
VIRAL VECTOR MANUFACTURE
17:00

Lentiviral vector production for advanced therapies

Panel discussion
VIRAL VECTOR MANUFACTURE
17:20

Panel discussion: process development for next generation therapeutics

18:00

Close of Conference for the day - Please join us for an evening drinks reception at the iconic Emirates Stadium

last published: 06/Dec/19 09:35

VIRAL VECTOR MANUFACTURE, Wednesday 1 April 2020

08:55

Opening Remarks

Federico Mingozzi
09:00

Gene therapy 2.0: New clinical data, therapeutic applications and next generation technologies

  • Latest updates on LUXTURNA studies to treat blindness, haemophilia and rare disease
  • Tackling the challenges of viral gene therapies i.e. immunogenicity
  • Developing the next generation of gene therapies, what does the future hold?
Steve Kanner
09:20

Next-generation gene editing technology for allogeneic immune cell therapeutics

  • Next-generation CRISPR-Cas9 technology
  • Significantly enhanced editing specificity
  • Editing in immune cells for generation of functionally tuned therapeutics
Adrian Woolfson
09:40

Repairing the human genome with designed zinc finger editing reagents

  • Overview of Sangamo’s zinc finger protein gene editing technology, including new innovations that facilitate specificity, precision, and gene editing efficiency
  • Will address specific examples of defined therapeutic applications including the generation of reagents suitable for use in tauopathies, Huntington’s disease, and lysosomal storage diseases
Frederic Chereau
10:00

In vivo gene editing paediatric patients with rare diseases

10:20

Networking Refreshments

Lawrence Thompson
VIRAL VECTOR MANUFACTURE
11:20

Plasmid DNA Control Strategy & AAV Production

Paul S Carter
VIRAL VECTOR MANUFACTURE
12:00

TBC Manufacturing viral vectors on a commercial level

Johannes Van Der Loo
VIRAL VECTOR MANUFACTURE
12:20

Challenges and concepts of designing a new GMP manufacturing facility at an academic centre

13:00

Neworking Lunch

Aisleen Mccoll-Carboni
VIRAL VECTOR MANUFACTURE
14:40

Phase-Appropriate Potency Assays for AAV Gene Therapy Products

Christine Le Bec
VIRAL VECTOR MANUFACTURE
15:40

TBC Strategies and Advances in AAV Vector Characterization: Product-Related Impurities

16:20

Networking refreshments

last published: 06/Dec/19 09:35